Mounjaro info: the practical facts before you decide anything

You've heard the results figure, here's what's behind it

Most people searching for Mounjaro info have already seen the headline percentage. The number comes from SURMOUNT-1, a 72-week trial involving 2,539 adults with obesity and no diabetes. At the 15 mg dose, participants lost an average of around 20–21% of their body weight. That's a meaningful figure, but three things are worth knowing before you treat it as a personal prediction.

First, it's an average across a large group; individual results vary based on starting weight, diet, activity and how the body responds to tirzepatide. Second, the trial ran alongside a reduced-calorie diet and increased physical activity, the injection supported those changes, not replaced them. Third, SURMOUNT-1 participants reached 15 mg only after gradual titration over several months. The tirzepatide overview on this site walks through the full evidence picture if you want to go deeper. The short version: the trial results, published in the New England Journal of Medicine, are the strongest published evidence available for any licensed weight-loss medicine in the UK right now, and they are what underpins NICE's positive appraisal.

The 2.5 mg starting dose exists specifically to let your system adjust before any real dose effect kicks in. Think of it as the calibration phase. Most people tolerate it without significant side effects; the higher doses do more of the clinical work.

Side effects: the ones most people actually experience

The side-effect profile for Mounjaro is led by the gut. Nausea is the most reported, followed by constipation, diarrhoea, vomiting and indigestion. These tend to be most noticeable in the first week or two after starting or after a dose step up, and for most people they ease off as the body adjusts. Staying hydrated matters more than most patients expect, particularly if nausea is putting them off drinking.

A handful of side effects need more urgent attention. Severe, persistent stomach pain that spreads towards the back (with or without vomiting) should prompt a call to 111 or a GP, because acute pancreatitis is a known but infrequent risk with GLP-1 medicines; the MHRA highlighted this specifically in a January 2026 Drug Safety Update. Gallbladder symptoms, signs of an allergic reaction and sudden mood changes are also listed in the patient information leaflet. The information leaflet guide covers what the full PIL says in plain language.

One quick habit worth building: before each weekly injection, check the pen looks as expected, clear, colourless solution, no particles, no damage to the pen body. It takes under a minute and is worth making routine. The NHS tirzepatide page sets out the full side-effect list in patient-readable form.

Questions about mood and Mounjaro come up regularly; there's a dedicated page on emotional side effects for anyone who wants to read about that specifically.

Who can get it and which route applies to you

The licensed eligibility for private prescription covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. Lower thresholds of 2.5 kg/m² apply for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. BMI alone doesn't settle the question, a prescriber considers the full clinical picture, including any medicines that might interact with tirzepatide.

NHS access to Mounjaro exists but is phased and carries strict criteria. From June 2025, the first NHS cohort requires a BMI of 40 or above plus four or more specific weight-related conditions. A second cohort (BMI 35–39.9 plus four or more conditions) opened in June 2026. GP practices can prescribe under the 2026 contract but are not required to, so availability varies. For people who don't meet the current NHS thresholds or prefer not to wait, a private prescription through a regulated pharmacy is the practical alternative. If you're unsure whether your GP knows you're exploring this, the page on taking Mounjaro without telling your GP addresses the considerations honestly.

On cost context: Eli Lilly raised the UK list price significantly from September 2025, with the highest-dose pen's list price moving to around £330. Private providers typically price between £149 and £375 per month depending on dose and service. A fuller breakdown of what drives those figures lives on the Mounjaro price increase page.

Getting started with a private prescription through nume

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated process. Identity is verified by photo ID, and weight is confirmed via a short video check rather than self-declaration alone. Those steps aren't bureaucracy for its own sake; they're what make it possible to prescribe safely at a distance.

If you're approved, medicine is dispatched the same day for orders placed before noon on a weekday, arriving the next working day via DPD in plain, unbranded packaging. There are no subscriptions and no auto-renewals. Each repeat order goes through clinical review again, so dose changes are assessed properly rather than just processed. Our clinical team and the about us page give a clearer picture of how that oversight works in practice.

If you want more detail before deciding anything, the Mounjaro patient information page covers the clinical specifics in full. Ready to see whether you're eligible? Check your eligibility with a free consultation, there's no obligation, and the clinical review happens the same day.